Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come.
The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal surfaces aiming to modulate the immune response. Savin says this might help to control various autoimmune diseases such as Crohn’s and Multiple Sclerosis (MS).
Foralumab has also been clinically tested with interesting results in COVID-19 patients to alleviate any immune overreaction. Mucosal delivery is an innovative approach and foralumab is in early-stage clinical development.
Read Dr John Savin's outlook report: Controlling disease using a safe, nasal and oral antibody